Pharming Group N.V. (PHAR) Total Debt (2019 - 2021)

Pharming (PHAR) has disclosed Total Debt for 3 consecutive years, with $165000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Total Debt fell 99.33% year-over-year to $165000.0, compared with a TTM value of $165000.0 through Dec 2021, down 99.33%, and an annual FY2021 reading of $165000.0, down 99.3% over the prior year.
  • Total Debt was $165000.0 for Q4 2021 at Pharming, down from $24.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $38.9 million in Q4 2019 and bottomed at $165000.0 in Q4 2021.
  • Average Total Debt over 3 years is $21.2 million, with a median of $24.5 million recorded in 2020.
  • The sharpest move saw Total Debt plummeted 37.03% in 2020, then crashed 99.33% in 2021.
  • Year by year, Total Debt stood at $38.9 million in 2019, then tumbled by 37.03% to $24.5 million in 2020, then plummeted by 99.33% to $165000.0 in 2021.
  • Business Quant data shows Total Debt for PHAR at $165000.0 in Q4 2021, $24.5 million in Q4 2020, and $38.9 million in Q4 2019.